Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | ATP4A | P20648 | 1/20 | 0.31 |
| ▸ | ATP4B | P51164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730017 | 0.91 | PSEN1 (0.34) | PPARDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4726101 | 0.89 | TRPV3 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4780947 | 0.85 | ATP4A (0.34) | PPARDATP4AATP4B | |
| SCHEMBL4730015 | 0.81 | PPARD (0.34) | PPARDATP4AATP4B | |
| SCHEMBL4726900 | 0.80 | ERBB2 (0.41) | ATP4AATP4B | |
| SCHEMBL4728989 | 0.80 | TRPV3 (0.34) | PPARDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4730718 | 0.78 | GRM2 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4599860 | 0.76 | ATP4A (0.37) | PPARDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4728357 | 0.73 | ERBB2 (0.37) | PPARDATP4AATP4B | |
| SCHEMBL4591853 | 0.72 | ATP4A (0.37) | PPARDATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008034579-A1 | 2-HETEROCYCLYL-5-PHENOXYMETHYLPYRIDINE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |